Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients

• Status: Not yet recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to compare the efficacy and safety of colistin versus lactulose for secondary prophylaxis of overt hepatic encephalopathy in patients with liver cirrhosis.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Madonna Magdy Fahmy
• Treatments: Colistin; Lactulose

Criteria

Inclusion Criteria:

• • Age >18 years.

• Patients with liver cirrhosis and previous history of recovery from hepatic encephalopathy.

Exclusion Criteria:

• • History of taking lactulose in past 7 days

• Patients on secondary prophylaxis for spontaneous bacterial peritonitis

• Patients on psychoactive drugs, such as antidepressants or sedatives

• Previous transjugular intrahepatic portosystemic shunts or shunt surgery

• Significant comorbid illness such as heart, respiratory, or neurological disease such as Alzheimer's disease and Parkinson's disease

• Hepatocellular carcinoma or other neoplasias that could shorten life expectancy

• Recent infection or antibiotic use within last 6 weeks

• Recent gastrointestinal bleeding in the past 6 weeks

• Renal insufficiency, myasthenia gravis.

• Hypersensitivity to colistin sulfate.

• Pregnancy or lactation

• Alcohol intake